Literature DB >> 21859388

Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.

Luciana Trilles1, Wieland Meyer, Bodo Wanke, Josep Guarro, Marcia Lazéra.   

Abstract

Members of the Cryptococcus neoformans/C. gattii species complex are grouped into eight molecular types, differing in their epidemiology, disease severity and geographic range. Recent in vitro antifungal susceptibility studies of isolates of the complex revealed contradictory results. The objective of the present study was to assess if this variation is random or correlates with different molecular types by testing the in vitro antifungal susceptibility of 18 C. neoformans (VNI), 11 C. gattii (VGI) and 38 C. gattii (VGII) strains from Brazil to eight antifungal drugs using the CLSI microdilution method. We herein report that the molecular type VGII is the least susceptible genotype, followed by VGI and VNI. This indicates a clear correlation between antifungal susceptibilities and genotypes of the causative cryptococcosis agents, emphasizing the importance of determining the molecular type as part of the clinical diagnostic process to enable an informed decision as to the most appropriate antifungal treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859388     DOI: 10.3109/13693786.2011.602126

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  34 in total

1.  Cryptococcus gattii as an important fungal pathogen of western North America.

Authors:  Kieren A Marr
Journal:  Expert Rev Anti Infect Ther       Date:  2012-06       Impact factor: 5.091

2.  Rapid differentiation of cryptic species within Cryptococcus gattii by a duplex PCR assay.

Authors:  Xiaobo Feng; Xiaohua Fu; Bo Ling; Lei Wang; Wanqing Liao; Weihua Pan; Zhirong Yao
Journal:  J Clin Microbiol       Date:  2013-07-03       Impact factor: 5.948

3.  The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; W David Nes; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

4.  Refractory and/or Relapsing Cryptococcosis Associated with Acquired Immune Deficiency Syndrome: Clinical Features, Genotype, and Virulence Factors of Cryptococcus spp. Isolates.

Authors:  Erika Nascimento; Lucia H Vitali; Ludmilla Tonani; Marcia R Von Zeska Kress; Osvaldo M Takayanagui; Roberto Martinez
Journal:  Am J Trop Med Hyg       Date:  2016-02-29       Impact factor: 2.345

5.  Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.

Authors:  P F Herkert; F Hagen; G L de Oliveira Salvador; R R Gomes; M S Ferreira; V A Vicente; M D Muro; R L Pinheiro; J F Meis; F Queiroz-Telles
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-01       Impact factor: 3.267

6.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

Authors:  A Espinel-Ingroff; A Chowdhary; M Cuenca-Estrella; A Fothergill; J Fuller; F Hagen; N Govender; J Guarro; E Johnson; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; L Trilles; S Kidd; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

7.  Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.

Authors:  Gloria M González; Néstor Casillas-Vega; Elvira Garza-González; Romel Hernández-Bello; Gildardo Rivera; Jesús Ancer Rodríguez; Virgilio Bocanegra-Garcia
Journal:  Folia Microbiol (Praha)       Date:  2015-06-25       Impact factor: 2.099

Review 8.  Cryptococcus gattii infections.

Authors:  Sharon C-A Chen; Wieland Meyer; Tania C Sorrell
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

9.  Cryptococcal meningitis in non-HIV patients in the State of Amazonas, Northern Brazil.

Authors:  Silviane Bezerra Pinheiro; Ednaira Sullany Sousa; Ana Claúdia Alves Cortez; Diego Fernando da Silva Rocha; Lizandra Stephany Fernandes Menescal; Valéria Soares Chagas; Aline Stephanie Pérez Gómez; Kátia Santana Cruz; Lucilaide Oliveira Santos; Marla Jalene Alves; Ani Beatriz Jackisch Matsuura; Bodo Wanke; Luciana Trilles; Hagen Frickmann; João Vicente Braga de Souza
Journal:  Braz J Microbiol       Date:  2020-10-06       Impact factor: 2.476

10.  Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.

Authors:  Mai Lee Yang; John Uhrig; Kiem Vu; Anil Singapuri; Michael Dennis; Angie Gelli; George R Thompson
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.